JP Morgan Sticks To Its Buy Note For Scholar Rock Holding Corp By Investing.com
JP Morgan analyst Anupam Rama maintained a buy rating on Scholar Rock Holding (NASDAQ 🙂 Corp on Friday, setting a price target of $ 55, or about 86.19% above the current price of $ 29.54.
Rama is waiting Scholar Rock Holding Corp to post earnings per share (EPS) of $ -1.02 for the fourth quarter of 2021.
The current consensus between 3 TipRanks Analysts are for a strong buy rating of shares of Scholar Rock Holding, with an average price target of $ 61.67.
Analysts’ price targets range from a high of $ 74 to a low of $ 55.
In its latest earnings report, released on 09/30/2021, the company reported quarterly revenue of $ 5.46 million and net income of -37.08 million. The company’s market capitalization is $ 1.04 billion.
According to TipRanks.com, Anupam Rama, analyst at JP Morgan is currently rated with 4 stars on a 0 to 5 star rating scale, with an average performance of 6.6% and a success rate of 44.24%.
Scholar Rock Holding Corp. is a biopharmaceutical company dedicated to the development and discovery of innovative drugs. The company offers a proprietary platform designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Fusion media or anyone involved with Fusion Media will accept no responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.